Abstract
Abstract: :
Purpose: Currently, there is no effective treatment for adenoviral conjunctivitis. We evaluated the antiviral inhibitory effect of new compound, sulfated sialyl lipid (NMSO3) against adenovirus (AdV) in vitro. We also analyzed the mechanism of the anti-AdV activity of NMSO3. Methods: AdV used were three prototype strains and three clinical isolated strains. These clinical strains were isolated from patients with adenoviral keratoconjunctivitis. NMSO3 was provided by Microbiotix Inc. 50% effective concentration (EC50) and 50% cytotoxic concentration (CC50) were determined for AdV infection in HEp-2 cells using 3-(4,5-dimetylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) methods. Results: EC50 of NMSO3 against replication of all prototype AdV strains was 0.21-0.71 mg/ml. All clinical strains were also the same antiviral effects. On the other hand, the CC50 of NMSO3 was more than 1000 mg/ml. NMSO3 exhibited minimal cytotoxicity against HEp-2 cells. NMSO3 inhibited AdV infection of HEp-2 cells only when added during virus adsorption. Conclusion: NMSO3 inhibited the replication of all AdV serotypes tested. NMSO3 was the most potent and selective anti-AdV compound. The mechanism of anti-AdV activity by NMSO3 involves inhibition of viral adsorption to cells.
Keywords: 307 adenovirus • 322 antiviral drugs • 366 conjunctivitis